| pubmed-article:17361205 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17361205 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:17361205 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:17361205 | lifeskim:mentions | umls-concept:C0242957 | lld:lifeskim |
| pubmed-article:17361205 | lifeskim:mentions | umls-concept:C1514559 | lld:lifeskim |
| pubmed-article:17361205 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:17361205 | lifeskim:mentions | umls-concept:C0439659 | lld:lifeskim |
| pubmed-article:17361205 | lifeskim:mentions | umls-concept:C1521871 | lld:lifeskim |
| pubmed-article:17361205 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:17361205 | pubmed:dateCreated | 2007-3-15 | lld:pubmed |
| pubmed-article:17361205 | pubmed:abstractText | The relationship between HER-2 overexpression and gene amplification is well evaluated in breast cancers but remains unclear or controversial in many other tumor entities. Therefore, we tested the HER-2 status in more than 120 different tumor entities. 5751 tumor samples were analyzed on TMAs by immunohistochemistry (Hercept-Test, DAKO) and fluorescence in situ hybridization (PathVysion, Abbott-Vysis) under highly standardized conditions. HER-2 overexpression (score 2/3+) and amplification occurred most often in breast cancers but was also seen in 18 other tumor entities including cancers of the urinary bladder (amplification in 14.3%, overexpression in 6.7%), stomach (8.3/4.9%), endometrium (6.6/6.8%), lung (2.8/3.1%) and ovary (2.3/1.2%). Remarkably, a strong association between overexpression and amplification was seen in all examined cancer entities. Trastuzumab therapy is highly efficient in HER-2 amplified breast cancer both in metastatic disease and as an adjuvant therapy. A variety of other tumor entities including frequent neoplasms and cancers with often limited therapeutic options have similar patterns of HER-2 alterations as observed in breast cancer (ie high overexpression due to high level gene amplification). Such tumor entities should be carefully evaluated for a possible utility of trastuzumab treatment. | lld:pubmed |
| pubmed-article:17361205 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17361205 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17361205 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17361205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17361205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17361205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17361205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17361205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17361205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17361205 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17361205 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:17361205 | pubmed:issn | 0893-3952 | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:SauterGuidoG | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:TerraccianoLu... | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:SimonRonaldR | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:TornilloLuigi... | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:SeemayerChris... | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:GlatzKatharin... | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:MirlacherMart... | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:LugliAlessand... | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:SpichtinHansp... | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:TapiaCoyaC | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:NovotnyHedvik... | lld:pubmed |
| pubmed-article:17361205 | pubmed:author | pubmed-author:HorcicMiloM | lld:pubmed |
| pubmed-article:17361205 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17361205 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:17361205 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17361205 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17361205 | pubmed:pagination | 192-8 | lld:pubmed |
| pubmed-article:17361205 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:meshHeading | pubmed-meshheading:17361205... | lld:pubmed |
| pubmed-article:17361205 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17361205 | pubmed:articleTitle | Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. | lld:pubmed |
| pubmed-article:17361205 | pubmed:affiliation | Institute of Pathology, University of Basel, Basel, Switzerland. | lld:pubmed |
| pubmed-article:17361205 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17361205 | pubmed:publicationType | Comparative Study | lld:pubmed |
| entrez-gene:2064 | entrezgene:pubmed | pubmed-article:17361205 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17361205 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17361205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17361205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17361205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17361205 | lld:pubmed |
